Trials / Completed
CompletedNCT01316822
A Study of ARRY-382 in Patients With Selected Advanced or Metastatic Cancers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Array Biopharma, now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1 study during which patients with advanced cancer will receive investigational study drug ARRY-382. Patients will receive increasing doses of study drug in order to achieve the highest dose of the study drug possible that will not cause unacceptable side effects. Patients will be followed to see what side effects and effectiveness the study drug has, if any, in treating the cancer. Approximately 50 patients from the US will be enrolled in this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ARRY-382, cFMS inhibitor; oral | multiple dose, escalating |
Timeline
- Start date
- 2011-03-01
- Primary completion
- 2012-10-01
- Completion
- 2012-10-01
- First posted
- 2011-03-16
- Last updated
- 2020-09-21
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01316822. Inclusion in this directory is not an endorsement.